目的探索脑血管病临床决策支持系统(clinical decision support system,CDSS)对卒中医疗服务质量关键绩效指标改进是否具有积极作用。方法回顾性连续纳入首都医科大学附属北京天坛医院血管神经病学2病区应用脑血管病CDSS前(2020年1—11...目的探索脑血管病临床决策支持系统(clinical decision support system,CDSS)对卒中医疗服务质量关键绩效指标改进是否具有积极作用。方法回顾性连续纳入首都医科大学附属北京天坛医院血管神经病学2病区应用脑血管病CDSS前(2020年1—11月)住院治疗的缺血性卒中患者作为对照组,应用脑血管病CDSS后(2021年1—11月)收治的缺血性卒中患者作为干预组,比较两组患者的基线特征和缺血性卒中医疗服务质量关键绩效指标,评估脑血管病CDSS对卒中医疗服务质量的影响。结果本研究共纳入1331例患者,其中对照组651例,干预组680例。对照组平均年龄为(71.7±11.8)岁,男性490例(75.3%);干预组平均年龄(72.3±10.2)岁,男性498例(73.2%)。缺血性卒中医疗服务质量关键绩效指标中,干预组入院48 h内不能行走患者进行深静脉血栓预防率(86.3%vs.65.0%,P<0.01)、出院时患者抗栓治疗率(98.1%vs.96.2%,P=0.03)、出院时合并心房颤动的患者抗凝治疗率(70.1%vs.44.2%,P<0.01)均高于对照组。结论脑血管病CDSS有助于改善缺血性卒中患者的医疗服务质量关键绩效指标。展开更多
BACKGROUND Drug-induced liver injury(DILI)is one of the most common adverse events of medication use,and its incidence is increasing.However,early detection of DILI is a crucial challenge due to a lack of biomarkers a...BACKGROUND Drug-induced liver injury(DILI)is one of the most common adverse events of medication use,and its incidence is increasing.However,early detection of DILI is a crucial challenge due to a lack of biomarkers and noninvasive tests.AIM To identify salivary metabolic biomarkers of DILI for the future development of noninvasive diagnostic tools.METHODS Saliva samples from 31 DILI patients and 35 healthy controls(HCs)were subjected to untargeted metabolomics using ultrahigh-pressure liquid chromatography coupled with tandem mass spectrometry.Subsequent analyses,including partial least squares-discriminant analysis modeling,t tests and weighted metabolite coexpression network analysis(WMCNA),were conducted to identify key differentially expressed metabolites(DEMs)and metabolite sets.Furthermore we utilized least absolute shrinkage and selection operato and random fores analyses for biomarker prediction.The use of each metabolite and metabolite set to detect DILI was evaluated with area under the receiver operating characteristic curves.RESULTS We found 247 differentially expressed salivary metabolites between the DILI group and the HC group.Using WMCNA,we identified a set of 8 DEMs closely related to liver injury for further prediction testing.Interestingly,the distinct separation of DILI patients and HCs was achieved with five metabolites,namely,12-hydroxydodecanoic acid,3-hydroxydecanoic acid,tetradecanedioic acid,hypoxanthine,and inosine(area under the curve:0.733-1).CONCLUSION Salivary metabolomics revealed previously unreported metabolic alterations and diagnostic biomarkers in the saliva of DILI patients.Our study may provide a potentially feasible and noninvasive diagnostic method for DILI,but further validation is needed.展开更多
文摘目的探索脑血管病临床决策支持系统(clinical decision support system,CDSS)对卒中医疗服务质量关键绩效指标改进是否具有积极作用。方法回顾性连续纳入首都医科大学附属北京天坛医院血管神经病学2病区应用脑血管病CDSS前(2020年1—11月)住院治疗的缺血性卒中患者作为对照组,应用脑血管病CDSS后(2021年1—11月)收治的缺血性卒中患者作为干预组,比较两组患者的基线特征和缺血性卒中医疗服务质量关键绩效指标,评估脑血管病CDSS对卒中医疗服务质量的影响。结果本研究共纳入1331例患者,其中对照组651例,干预组680例。对照组平均年龄为(71.7±11.8)岁,男性490例(75.3%);干预组平均年龄(72.3±10.2)岁,男性498例(73.2%)。缺血性卒中医疗服务质量关键绩效指标中,干预组入院48 h内不能行走患者进行深静脉血栓预防率(86.3%vs.65.0%,P<0.01)、出院时患者抗栓治疗率(98.1%vs.96.2%,P=0.03)、出院时合并心房颤动的患者抗凝治疗率(70.1%vs.44.2%,P<0.01)均高于对照组。结论脑血管病CDSS有助于改善缺血性卒中患者的医疗服务质量关键绩效指标。
基金supported by the National Natural Science Foundation of China (82230118)the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202005)。
基金Supported by Medical Education Association Foundation of China,No.2020KTY001National Natural Science Foundation of China,No.81673806National Natural Science Foundation Youth Fund,No.82104702.
文摘BACKGROUND Drug-induced liver injury(DILI)is one of the most common adverse events of medication use,and its incidence is increasing.However,early detection of DILI is a crucial challenge due to a lack of biomarkers and noninvasive tests.AIM To identify salivary metabolic biomarkers of DILI for the future development of noninvasive diagnostic tools.METHODS Saliva samples from 31 DILI patients and 35 healthy controls(HCs)were subjected to untargeted metabolomics using ultrahigh-pressure liquid chromatography coupled with tandem mass spectrometry.Subsequent analyses,including partial least squares-discriminant analysis modeling,t tests and weighted metabolite coexpression network analysis(WMCNA),were conducted to identify key differentially expressed metabolites(DEMs)and metabolite sets.Furthermore we utilized least absolute shrinkage and selection operato and random fores analyses for biomarker prediction.The use of each metabolite and metabolite set to detect DILI was evaluated with area under the receiver operating characteristic curves.RESULTS We found 247 differentially expressed salivary metabolites between the DILI group and the HC group.Using WMCNA,we identified a set of 8 DEMs closely related to liver injury for further prediction testing.Interestingly,the distinct separation of DILI patients and HCs was achieved with five metabolites,namely,12-hydroxydodecanoic acid,3-hydroxydecanoic acid,tetradecanedioic acid,hypoxanthine,and inosine(area under the curve:0.733-1).CONCLUSION Salivary metabolomics revealed previously unreported metabolic alterations and diagnostic biomarkers in the saliva of DILI patients.Our study may provide a potentially feasible and noninvasive diagnostic method for DILI,but further validation is needed.
